Same-day CAR-T production is established and refined through the comparison of novel vector and gene-editing strategies with classical methods. Both processes are then standardized to ensure consistent, clinical-scale use. It develops cutting-edge analytical assays - leveraging CRISPR off-target profiling, 3D ex vivo efficacy screens, and cytokine-release monitoring - to qualify edited cells for safety and potency. Finally, it conducts paired comparisons of the new rapid workflow versus traditional ex vivo culture to demonstrate equivalence or superiority in product quality.
Kevin Gutshall is the Chief CommercialOfficer at Kytopen, where he leads the company’s global growth and commercialstrategy. In 2025, he led the launch and global commercialization of theFlowfect® platform, advancing next-generation cellular engineering solutions for the cell therapy industry.
He is an accomplished commercialand business development executive with proven expertise in portfolio strategy, strategic partnerships, and M&A. He has held senior leadership roles acrosshigh-growth biotechnology companies, consistently driving revenue expansion and long-term value creation.
Prior to joining Kytopen, Kevin served as Chief Business Officer at CellFE, a cellular engineering startup. He previously held the role of Vice President of Strategy and Corporate Development at MaxCyte, where he led corporate growth initiatives, built high-value strategic partnerships, and guided M&A strategy. Earlier in his career, Kevin served as Director of Corporate Development at MilliporeSigma andas Head of Business Development at Sigma-Aldrich, further establishing his reputation as a strategic leader in the Life Sciences.
Kevin’s role will be to provide business and commercial oversight for the Kytopen team into the consortium.
Stephanie Camacho, PhD, is Vice President of Marketing at Kytopen, where she oversees the marketing strategy and execution, as well as product management for its cutting-edge RUO and GMP Flowfect® cellular engineering technology.
A seasoned life sciences leader with over two decades of experience, Stephanie specializes in commercializing transformative biotechnologies, including capital equipment and GMP-ready platforms. She has a strong track record in driving growth through product strategy, building high-performing teams, and developing strategic partnerships across emerging and established organizations. Prior to joining Kytopen, Stephanie was Senior Director, Marketing at CellFE, a cellular engineering startup.
Stephanie holds a PhD in biochemistry and immunology from Freie Universität Berlin, Germany.
Chris Abraham, PhD, is the Director of Application Development at Kytopen, where he leads the development of novel applications and platform optimization for Flowfect® technology. He leads a specialized team of field application scientists, driving strategic collaborations with external partners to accelerate the discovery and manufacturing of gene-modified cell therapies.
With over a decade of experience, Chris has dedicated his career to advancing non-viral gene delivery through expert workflow and assay development. His extensive expertise in RNP-based workflowsand high-throughput screening was honed through leadership roles at pioneering biotechnology firms, including Inscripta, Inc and Artisan Bio.
Chris earned his PhD in Microbiology from the University of Colorado Anschutz Medical Campus and completed postdoctoral research funded by the American Cancer Society at the University of Colorado Boulder, focusing on CRISPR-based functional genomics in cancer models.
Chris will be a scientific lead for the transfection workflows and processing.
John Zhao is the Director of Process Development at Kytopen, where he leads a multi-disciplinary team advancing non-viral payload delivery technologies for cellular therapies. His oversees the development and optimization of consumables and reagents for the company’s Flowfect® platform, enabling efficient, scalable delivery of genetic material across diverse cell types.
With over a decade of experience in cell and gene therapy, John brings deep expertise spanning early-stage research, process development, andcommercial-scale manufacturing.
John earned a Master of Science in Biochemistry and Molecular Biology at the University of Louisville, Kentucky.
John will be a scientific lead for the transfection workflows and processing.
